IVD China this week: Snibe, Edan, Livzon and Wepuretech

Both revenue and net profit have increased by over 30%! Snibe 2023 half-yearly report released

On August 24th, Snibe released its 2023 semiannual report. During the reporting period, the company achieved a revenue of CNY1.865 billion, a year-on-year increase of 31.64%. The net profit attributable to shareholders of the listed company was CNY750 million, a year-on-year increase of 31.68%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY687 million, a year-on-year increase of 31.21%. Basic earnings per share of CNY0.9547.

Edan released a semiannual report, with directors, executives, major shareholders, and others promising not to reduce their holdings within six months

Edan released its 2023 semiannual report, with a revenue of CNY1.090 billion, a year-on-year increase of 27.08%. The net profit attributable to shareholders of the listed company was CNY207 million, a year-on-year increase of 37.65%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY192 million, a year-on-year increase of 51.07%; Basic earnings per share of CNY0.3572.

On August 24th, Edan announced that directors, executives, and major shareholders holding 5% or more have promised not to reduce their holdings of company stocks in any form for the next 6 months.

Livzon's 2023 midterm report

According to the 2023 midterm report of Livzon, the operating revenue for the current period was CNY6689918114.87, an increase of 6.15% compared to the previous period's CNY6302565210.60. This indicates that the company has achieved good performance in operating revenue, and the growth of operating revenue has a positive driving effect on the company's development.

Wepuretech has completed nearly CNY100 million in Pre A round of financing

Recently, Wepuretech has completed nearly CNY100 million in Pre A round of financing, led by Junlian Capital, with Zhongda Venture Capital, Dunjun Asset, Jingtao Venture Capital, Chunxi Investment, and Weisheng Biotechnology jointly investing. The funds will be used for production base construction and research and development investment.

​